Associated Banc Corp trimmed its holdings in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 34.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,010 shares of the medical research company’s stock after selling 11,896 shares during the quarter. Associated Banc Corp’s holdings in PAREXEL International Corporation were worth $2,000,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. increased its position in shares of PAREXEL International Corporation by 22,876.6% during the first quarter. BlackRock Inc. now owns 5,513,456 shares of the medical research company’s stock valued at $347,955,000 after acquiring an additional 5,489,460 shares during the last quarter. Credit Suisse AG increased its position in shares of PAREXEL International Corporation by 1,897.2% during the first quarter. Credit Suisse AG now owns 2,093,297 shares of the medical research company’s stock valued at $132,108,000 after acquiring an additional 1,988,488 shares during the last quarter. State Street Corp increased its position in shares of PAREXEL International Corporation by 2.1% during the first quarter. State Street Corp now owns 1,673,118 shares of the medical research company’s stock valued at $105,586,000 after acquiring an additional 34,328 shares during the last quarter. Nomura Holdings Inc. increased its position in shares of PAREXEL International Corporation by 189.6% during the first quarter. Nomura Holdings Inc. now owns 1,381,087 shares of the medical research company’s stock valued at $87,088,000 after acquiring an additional 904,236 shares during the last quarter. Finally, Alpine Associates Management Inc. purchased a new stake in shares of PAREXEL International Corporation during the second quarter valued at approximately $113,716,000. 87.48% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “PAREXEL International Corporation (PRXL) Shares Sold by Associated Banc Corp” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/14/parexel-international-corporation-prxl-shares-sold-by-associated-banc-corp.html.

PAREXEL International Corporation (PRXL) traded up 0.01% during mid-day trading on Thursday, reaching $87.94. The company’s stock had a trading volume of 75,422 shares. The company has a 50-day moving average price of $87.67 and a 200-day moving average price of $77.32. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $87.96. The firm has a market cap of $4.50 billion, a PE ratio of 42.69 and a beta of 0.79.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. The business had revenue of $557.20 million during the quarter, compared to analyst estimates of $537.59 million. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. During the same period in the previous year, the business earned $0.94 EPS. On average, equities research analysts expect that PAREXEL International Corporation will post $3.95 earnings per share for the current year.

A number of analysts recently commented on the company. Zacks Investment Research raised PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price target for the company in a research report on Thursday, August 31st. BidaskClub downgraded PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Jefferies Group LLC reaffirmed a “hold” rating and set a $88.10 price target on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Barclays PLC downgraded PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target for the company. in a research report on Tuesday, June 20th. Finally, Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company. PAREXEL International Corporation currently has an average rating of “Hold” and an average price target of $75.92.

PAREXEL International Corporation Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.